Arrowhead Pharmaceuticals has seen significant stock transactions by its top executives in late December 2025. Chief Executive Officer, Christopher Richard Anzalone, sold a total of 51,726 shares of common stock for a total amount of $3,575,574. The sales were conducted in two transactions, with shares sold at weighted average prices of $69.33 and $68.69, respectively. Following these transactions, Anzalone directly owns 3,805,926 shares of the company.

Mauro Ferrari, a Director at Arrowhead Pharmaceuticals, sold 7,530 shares of Common Stock at a price of $70.0 per share, totaling $527,100. After this sale, Ferrari directly owns 69,053 shares of the company. His sale was executed under a 10b5-1 trading plan.

Reporter Name	Relationship	Type	Amount	SEC Filing
Anzalone Christopher Richard	Chief Executive Officer	Sell	$3,575,574	Form 4
Ferrari Mauro	Director	Sell	$527,100	Form 4

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Arrowhead Pharmaceuticals Executives Conduct Major Stock Transactions